Cargando…
BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
Checkpoint molecules such as programmed cell death protein-1 (PD-1) and its ligand PD-L1 are critically required for tumor immune escape. The objective of this study was to investigate tumoral PD-1 and PD-L1 mRNA-expression in a cohort of ovarian cancer (OC) patients in relation to tumor mutations....
Autores principales: | Wieser, Verena, Gaugg, Inge, Fleischer, Martina, Shivalingaiah, Giridhar, Wenzel, Soeren, Sprung, Susanne, Lax, Sigurd F., Zeimet, Alain G., Fiegl, Heidelinde, Marth, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915132/ https://www.ncbi.nlm.nih.gov/pubmed/29707124 http://dx.doi.org/10.18632/oncotarget.24770 |
Ejemplares similares
-
BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in
ovarian cancer
por: Tsibulak, Irina, et al.
Publicado: (2018) -
The miR-34 family and its clinical significance in ovarian cancer
por: Welponer, Hannah, et al.
Publicado: (2020) -
Clinical Impact of RANK Signalling in Ovarian Cancer
por: Wieser, Verena, et al.
Publicado: (2019) -
Tumor necrosis factor receptor modulator spermatogenesis‐associated protein 2 is a novel predictor of outcome in ovarian cancer
por: Wieser, Verena, et al.
Publicado: (2019) -
High RIG‐I expression in ovarian cancer associates with an immune‐escape signature and poor clinical outcome
por: Wolf, Dominik, et al.
Publicado: (2019)